Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents

American Journal of Neuroradiology

Volumn 33, Issue 8, 2012, Pages 1586-1590

  Shinohara, Russell T ^a,c   Goldsmith, J ^a   Mateen, F J ^b   Crainiceanu, C ^a   Reich, D S ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM CHELATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE; WHITE MATTER;

ADULT; BLOOD-BRAIN BARRIER; BRAIN; CONTRAST MEDIA; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ROC CURVE;

EID: 84866412406     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2997     Document Type: Article

References (15)

1. Raine CS, McFarland HF, Tourtellotte WW. Multiple Sclerosis: Clinical and Pathogenic Basis. London, UK: Chapman and Hall; 1997
2. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68 (Pubitemid 38391962)
3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
4. Physician Fee Schedule. Centers for Medicare and Medicaid Services. http://www.cms.gov/apps/physician-fee-schedule/license-agreement.aspx. Accessed September 13, 2011
5. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008;67(supple 3):iii66-69
6. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4:461-69
7. Moren-Romero JA, Sequira S, Mascaro JMJ, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007;157:783-87
8. Dillman JR, Ellis JH, Cohan RH, et al. Frequency and severity of acute allergiclike reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 2007;189:1533-38 (Pubitemid 350174833)
9. Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009;193:1124-27
10. Kataoka H, Taoka T, Ueno S. Early contrast-enhanced magnetic resonance imaging with fluid-attenuated inversion recovery in multiple sclerosis. J Neuroimaging 2009;19:246-49
11. Bagnato F. Uncovering and characterizing multiple sclerosis lesions: the aid of fluid-attenuated inversion recovery images in the presence of gadolinium contrast agent. J Neuroimaging 2009;19:201-04
12. Sled JG, Zijdenbox AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97 (Pubitemid 128742012)
13. Carass A, Wheeler MB, Cuzzocreo J, et al. A joint registration and segmentation approach to skull stripping. In: Proceedings of the IEEE International Symposium on Biomedical Imaging: From Nano to Macro, Chicago, Illinois; March 30-April 2, 2011:656-59
14. Moraal B, Wattjes MP, Geurts JJ, et al. Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 2010;255:154-63
15. Di CZ, Crainiceanu CM, Caffo BS, et al. Multilevel functional principal component analysis. Ann Appl Stat 2009;3:458-88